Senior AstraZeneca Executive Issues Warning For Future Of UK Lifesciences Industry
Despite Brexit, a new survey reveals optimism about the UK as a place to conduct clinical research and launch new medicines.
You may also be interested in...
The norms on securing market access are being rewritten for cell and gene therapies.
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.